Drug Trial Radar · NCT04479449
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
Last checked: Nov 20, 2026Latest source record: Mar 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Mar 18, 2019
Primary completion
Oct 19, 2020
Study completion Dec 18, 2020
Sponsor
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care. In this clinical trial, rtPA will be injected intravenously using an infusion device. If reperfusion is not occur in spite of rtPA therapy, endovascular therapy can be performed.
Conditions
- Ischemic Stroke
Interventions
SP-8203Drug
SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
PlaceboDrug
Placebo will be intravenously administered twice daily (intervals of 12 hours)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The neurological improvement evaluated by the National Institute of Health Stroke Scale (NIHSS)Time frame: Change from 0 day at 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.